Research programme: Tumour antigen-specific bispecific TCR T-cell therapy - Repertoire Immune Medicines
Latest Information Update: 22 Aug 2024
At a glance
- Originator Repertoire Immune Medicines
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 07 Aug 2024 Early research in Solid tumours in USA (Parenteral), prior to August 2024 (Repertoire Immune Medicines pipeline, August 2024)